Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NADK | O95544 | 2/20 | 0.61 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.60 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | GAPDH | P04406 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740341 | 1.00 | NADK (0.61) | NADKHSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL30237237 | 1.00 | NADK (0.61) | NADKHSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL28537245 | 0.92 | NADK (0.59) | NADKHSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL12376381 | 0.91 | NADK (0.60) | NADKHSPA5HSPA8RXFP1 | |
| SCHEMBL12360838 | 0.91 | NADK (0.60) | NADKHSPA5HSPA8RXFP1 | |
| SCHEMBL23548003 | 0.89 | HSPA8 (0.62) | HSPA5HSPA8RXFP1HSD17B10GAPDH | |
| SCHEMBL6388256 | 0.89 | HSPA8 (0.62) | HSPA5HSPA8RXFP1HSD17B10GAPDH | |
| SCHEMBL28087475 | 0.89 | HSPA8 (0.62) | HSPA5HSPA8RXFP1HSD17B10GAPDH | |
| SCHEMBL1737260 | 0.89 | HSPA8 (0.76) | HSPA5HSPA8RXFP1HSD17B10GAPDH | |
| SCHEMBL30484790 | 0.88 | HSPA8 (0.61) | HSPA5HSPA8RXFP1HSD17B10GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-9487553-B2 | Boranophosphate analogues of cyclic nucleotides | BIOLOG LIFE SCIENCE INSTITUTE FORSCHUNGSLABOR UND BIOCHEMICA-VERTRIEB GMBH (DE) | 2016-11-08 | — | — | US | disclosed |
| EP-2691403-B1 | NEW BORANOPHOSPHATE ANALOGUES OF CYCLIC NUCLEOTIDES | BIOLOG LIFE SCIENCE INST FORSCHUNGSLABOR UND BIOCHEMICA VERTRIEB GMBH (DE) | 2016-05-18 | — | — | EP | disclosed |
| EP-1511757-B1 | NEW COMPOUNDS FOR MODULATING THE ACTIVITY OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) | UNIV MEDISCH CENTRUM UTRECHT (NL) | 2015-11-04 | — | — | EP | disclosed |
| US-20140088033-A1 | NEW BORANOPHOSPHATE ANALOGUES OF CYCLIC NUCLEOTIDES | BIOLOG LIFE SCIENCE INSTITUTE FORSCHUNGSLABOR UND BIOCHEMICA-VERTRIEB GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-7906491-B2 | Compounds for modulating the activity of exchange proteins directly activated by cAMP (Epacs) | UNIVISITAIR MEDISCH CENTRUM UTRECHT (NL) | 2011-03-15 | — | — | US | disclosed |
| US-20060100166-A1 | Compounds for modulating the activity of exchange proteins directly activated by camp (epacs) | KYLIX B.V. (NL) | 2006-05-11 | — | — | US | disclosed |
| EP-1511757-A1 | NEW COMPOUNDS FOR MODULATING THE ACTIVITY OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) | Kylix B.V. (NL) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003104250-A1 | NEW COMPOUNDS FOR MODULATING THE ACTIVITY OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) | KYLIX, B. V. (NL) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100166-A1 | Compounds for modulating the activity of exchange proteins directly activated by camp (epacs) | RAPGEF3, CREB1, PDE4C | NADK 1131/4885HSPA5 2446/4885HSPA8 2621/4885 |
| US-20140088033-A1 | NEW BORANOPHOSPHATE ANALOGUES OF CYCLIC NUCLEOTIDES | NT5C2, NT5E, ENPP3 | NADK 760/4885HSPA5 1639/4885HSPA8 2358/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | NADK 2688/4885HSPA5 2282/4885HSPA8 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.